← 返回前沿论文

从肿瘤排斥食蟹猴模型中的 TIL(肿瘤浸润淋巴细胞)和循环淋巴细胞中分离具有肿瘤杀伤活性的 TCR 基因

英文原题:Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model.

PubMed 2021/12/06(内容时间) Mol Ther Oncolytics

研究概要

为了开发使用T细胞受体(TCR)工程化T细胞的有效过继细胞转移疗法,分离具有强效抗肿瘤活性的肿瘤反应性TCR至关重要。

中文摘要

为了开发使用T细胞受体(TCR)工程化T细胞的有效过继性细胞转移疗法,分离具有强效抗肿瘤活性的肿瘤反应性TCR至关重要。在人类中,已报道TIL(肿瘤浸润淋巴细胞)(TILs)含有表达肿瘤反应性TCR的CD8 + PD-1 + T细胞。表征非人灵长类动物肿瘤中TILs的肿瘤反应性,可能提高TCR工程化T细胞在临床前研究中的抗肿瘤活性。在本研究中,我们试图从食蟹猴肿瘤移植模型的TILs中分离CD8 + PD-1 + T细胞的TCR基因,该模型中肿瘤被CD8 + T细胞浸润并最终被排斥。我们分析了从TILs和循环淋巴细胞中的单个CD8 + PD-1 + T细胞获得的TCRα和β配对库,并鉴定出多个高频TCR配对,表明表达这些复现TCR的T细胞在响应肿瘤细胞时发生了克隆扩增。我们进一步表明,这些复现TCR在体外对肿瘤细胞表现出细胞毒性活性,并在移植肿瘤细胞的小鼠中表现出强效抗肿瘤活性。这些结果暗示,该肿瘤移植猕猴模型再现了人类TILs的关键特征,并可作为非人灵长类动物肿瘤模型临床前研究的平台。

展开英文摘要原文

To develop effective adoptive cell transfer therapy using T cell receptor (TCR)-engineered T cells, it is critical to isolate tumor-reactive TCRs that have potent anti-tumor activity. In humans, tumor-infiltrating lymphocytes (TILs) have been reported to contain CD8 + PD-1 + T cells that express tumor-reactive TCRs. Characterization of tumor reactivity of TILs from non-human primate tumors could improve anti-tumor activity of TCR-engineered T cells in preclinical research. In this study, we sought to isolate TCR genes from CD8 + PD-1 + T cells among TILs in a cynomolgus macaque model of tumor transplantation in which the tumors were infiltrated with CD8 + T cells and were eventually rejected. We analyzed the repertoire of TCRα and β pairs obtained from single CD8 + PD-1 + T cells in TILs and circulating lymphocytes and identified multiple TCR pairs with high frequency, suggesting that T cells expressing these recurrent TCRs were clonally expanded in response to tumor cells. We further showed that the recurrent TCRs exhibited cytotoxic activity to tumor cells in vitro and potent anti-tumor activity in mice transplanted with tumor cells. These results imply that this tumor transplantation macaque model recapitulates key features of human TILs and can serve as a platform toward preclinical studies of non-human primate tumor models.

论文信息

作者
Terada K、Kondo K、Ishigaki H、Nagashima A、Satooka H、Nagano S、Masuda K、Kawamura T
单位
Department of Biochemistry and Molecular Biology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.Japan
期刊
Molecular therapy oncolytics2022 Mar 17
原文标识
PubMed 35024435 · DOI 10.1016/j.omto.2021.12.003